WuXi Biologics (Cayman) Inc. ADR (1FW1)

Overview

WuXi Biologics (Cayman) Inc. stands as a pivotal entity within the biologics sector, specializing in a comprehensive range of solutions that span the entirety of the biologics discovery, development, and manufacturing process. Incorporated in 2014 and headquartered in Wuxi, China, the company extends its services not only within the People's Republic of China but also across North America, Europe, Singapore, Japan, South Korea, and Australia. WuXi Biologics operates through two principal segments: Biologics and XDC, engaging in a myriad of activities including consultation on biopharmaceutical technology, international sales contracting, testing and development of new testing technologies, alongside marketing and production of medicals. Furthermore, the company takes part in vaccine contract development and manufacturing organization (CDMO) activities, investment, and supplier operations, strengthening its position as a cornerstone in the biologics industry.

Products and Services

• Contract Research, Development, and Manufacturing Organization Platforms

  Includes a suite of solutions for biologic discovery, from concept to investigation new drug (IND) applications, seamlessly transitioning to Chemistry, Manufacturing and Controls (CMC) and downstream process development. This platform encompasses a variety of specialized technologies such as WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh.

• Consultation Services

  These services cover a broad range on biopharmaceutical technology, providing key insights and guidance through the complex landscape of biologics development and manufacturing.

• International Sales Contracting Services

  WuXi Biologics offers comprehensive sales contracting services that facilitate international operations, ensuring efficient and compliant access to global markets for biologics products.

• Testing and Development of Testing Technologies

  The company is deeply involved in the creation and improvement of testing technologies. This includes the development of innovative methods for testing biologics, ensuring safety and efficacy of the products developed under its umbrella.

• Sales and Marketing Services

  WuXi Biologics provides proficient sales and marketing strategies, essential for the successful launch and distribution of biologics products in a competitive market.

• Production and Sales of Medicals

  Engages in both the production and sales of medical products, leveraging its extensive manufacturing capabilities to cater to the demands of the biologics sector.

• Biologics Clinical and Manufacturing Services

  Offers a comprehensive range of services tailored to the clinical development and manufacturing phases of biologics production, ensuring high-quality standards and regulatory compliance.

• Vaccine Contract Development and Manufacturing Organization (CDMO)

  Specializes in vaccine development and manufacturing, providing a full suite of services from conceptualization to market delivery, highlighting its versatility in the biologics domain.

• Investment and Material Supplier Activities

  Embarks on strategic investment ventures and supplies materials necessary for biologics development and manufacturing, supporting the broader ecosystem of the biopharmaceutical industry.

• Research Service Agreement with BioNTech SE

  WuXi Biologics has entered into a notable research service agreement with BioNTech SE, focusing on the discovery and investigation of monoclonal antibodies for the development of next-generation therapeutic product candidates, showcasing its commitment to advancing biologics research and development.